Follow
Marco Colleoni
Marco Colleoni
Direttore, Divisione di Senologia Medica, Istituto Europeo di Oncologia, Milano
Verified email at ieo.it
Title
Cited by
Cited by
Year
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
42472013
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
21942015
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous …
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
The Lancet Oncology 17 (4), 425-439, 2016
17062016
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial
V Galimberti, BF Cole, S Zurrida, G Viale, A Luini, P Veronesi, P Baratella, ...
The lancet oncology 14 (4), 297-305, 2013
12732013
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 386 (10001), 1341-1352, 2015
12492015
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
11992017
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
AS Coates, A Keshaviah, B Thürlimann, H Mouridsen, L Mauriac, ...
Journal of clinical oncology 25 (5), 486-492, 2007
11402007
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss, M Buyse, ...
Journal of Clinical Oncology 28 (3), 509-518, 2010
10312010
Overall survival with palbociclib and fulvestrant in advanced breast cancer
NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ...
New England journal of medicine 379 (20), 1926-1936, 2018
10032018
Overall survival with ribociclib plus endocrine therapy in breast cancer
SA Im, YS Lu, A Bardia, N Harbeck, M Colleoni, F Franke, L Chow, J Sohn, ...
New England journal of medicine 381 (4), 307-316, 2019
8762019
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ...
New England Journal of Medicine 371 (2), 107-118, 2014
8692014
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ...
The Lancet Oncology 19 (7), 904-915, 2018
8642018
Adjuvant ovarian suppression in premenopausal breast cancer
PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ...
New England Journal of Medicine 372 (5), 436-446, 2015
8402015
Tailoring adjuvant endocrine therapy for premenopausal breast cancer
PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ...
New England Journal of Medicine 379 (2), 122-137, 2018
5942018
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
HJ Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, ...
Annals of Oncology 30 (10), 1541-1557, 2019
5812019
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
M Colleoni, A Rocca, MT Sandri, L Zorzino, G Masci, F Nole, G Peruzzotti, ...
Annals of Oncology 13 (1), 73-80, 2002
5742002
Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V
M Colleoni, Z Sun, KN Price, P Karlsson, JF Forbes, B Thürlimann, ...
Journal of clinical oncology 34 (9), 927, 2016
5722016
Very young women (< 35 years) with operable breast cancer: features of disease at presentation
M Colleoni, N Rotmensz, C Robertson, L Orlando, G Viale, G Renne, ...
Annals of Oncology 13 (2), 273-279, 2002
5342002
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
Y Shaked, E Henke, JML Roodhart, P Mancuso, MHG Langenberg, ...
Cancer cell 14 (3), 263-273, 2008
5182008
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
O Pagani, E Senkus, W Wood, M Colleoni, T Cufer, S Kyriakides, A Costa, ...
Journal of the National Cancer Institute 102 (7), 456-463, 2010
4952010
The system can't perform the operation now. Try again later.
Articles 1–20